Effect of long-term treatment with ursodiol on clinical and biochemical features and biliary bile acid metabolism in patients with primary biliary cirrhosis

A. K. Batta, G. Salen, R. Mirchandani, G. S. Tint, S. Shefer, M. Batta, J. Abroon, Christopher B O'Brien, J. R. Senior

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

The effect of ursodiol on the clinical and biochemical features, serum, urinary, and biliary bile acids was investigated over a 2-yr treatment period in 14 patients with primary biliary cirrhosis (stages II-IV). Pruritus and fatigue improved, and alkaline phosphatase and liver transferases declined significantly in all patients during therapy. In four patients, less inflammation was noted by liver biopsy after 2 yr, but histology of disease did not change. Serum and urinary bile acids were increased several-fold before treatment, with cholic acid predominating. Ursodiol accounted for 30% of biliary bile acids after administration (gallstone subjects ≃ 50%), and was conjugated with glycine and taurine in a ratio of 7.3:1. However, in the endogenous bile acids, the ratio increased from 1.2:1 to only 2.1:1. About 6% unconjugated bile acids were secreted into the bile (healthy controls < 1%). Thus, in patients with primary biliary cirrhosis, a larger fraction of free bile acids and a higher proportion of taurine-conjugated bile acids are secreted into the bile, compared with healthy controls. Ursodiol improves symptoms and histology with lower biliary enrichment with this bile acid.

Original languageEnglish
Pages (from-to)691-700
Number of pages10
JournalAmerican Journal of Gastroenterology
Volume88
Issue number5
StatePublished - Jan 1 1993
Externally publishedYes

Fingerprint

Ursodeoxycholic Acid
Biliary Liver Cirrhosis
Bile Acids and Salts
Taurine
Therapeutics
Bile
Histology
Cholic Acid
Liver
Gallstones
Pruritus
Transferases
Serum
Glycine
Fatigue
Alkaline Phosphatase
Inflammation
Biopsy

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Effect of long-term treatment with ursodiol on clinical and biochemical features and biliary bile acid metabolism in patients with primary biliary cirrhosis. / Batta, A. K.; Salen, G.; Mirchandani, R.; Tint, G. S.; Shefer, S.; Batta, M.; Abroon, J.; O'Brien, Christopher B; Senior, J. R.

In: American Journal of Gastroenterology, Vol. 88, No. 5, 01.01.1993, p. 691-700.

Research output: Contribution to journalArticle

Batta, A. K. ; Salen, G. ; Mirchandani, R. ; Tint, G. S. ; Shefer, S. ; Batta, M. ; Abroon, J. ; O'Brien, Christopher B ; Senior, J. R. / Effect of long-term treatment with ursodiol on clinical and biochemical features and biliary bile acid metabolism in patients with primary biliary cirrhosis. In: American Journal of Gastroenterology. 1993 ; Vol. 88, No. 5. pp. 691-700.
@article{a39532ff0ee6451db67f6c7a32e7e968,
title = "Effect of long-term treatment with ursodiol on clinical and biochemical features and biliary bile acid metabolism in patients with primary biliary cirrhosis",
abstract = "The effect of ursodiol on the clinical and biochemical features, serum, urinary, and biliary bile acids was investigated over a 2-yr treatment period in 14 patients with primary biliary cirrhosis (stages II-IV). Pruritus and fatigue improved, and alkaline phosphatase and liver transferases declined significantly in all patients during therapy. In four patients, less inflammation was noted by liver biopsy after 2 yr, but histology of disease did not change. Serum and urinary bile acids were increased several-fold before treatment, with cholic acid predominating. Ursodiol accounted for 30{\%} of biliary bile acids after administration (gallstone subjects ≃ 50{\%}), and was conjugated with glycine and taurine in a ratio of 7.3:1. However, in the endogenous bile acids, the ratio increased from 1.2:1 to only 2.1:1. About 6{\%} unconjugated bile acids were secreted into the bile (healthy controls < 1{\%}). Thus, in patients with primary biliary cirrhosis, a larger fraction of free bile acids and a higher proportion of taurine-conjugated bile acids are secreted into the bile, compared with healthy controls. Ursodiol improves symptoms and histology with lower biliary enrichment with this bile acid.",
author = "Batta, {A. K.} and G. Salen and R. Mirchandani and Tint, {G. S.} and S. Shefer and M. Batta and J. Abroon and O'Brien, {Christopher B} and Senior, {J. R.}",
year = "1993",
month = "1",
day = "1",
language = "English",
volume = "88",
pages = "691--700",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Effect of long-term treatment with ursodiol on clinical and biochemical features and biliary bile acid metabolism in patients with primary biliary cirrhosis

AU - Batta, A. K.

AU - Salen, G.

AU - Mirchandani, R.

AU - Tint, G. S.

AU - Shefer, S.

AU - Batta, M.

AU - Abroon, J.

AU - O'Brien, Christopher B

AU - Senior, J. R.

PY - 1993/1/1

Y1 - 1993/1/1

N2 - The effect of ursodiol on the clinical and biochemical features, serum, urinary, and biliary bile acids was investigated over a 2-yr treatment period in 14 patients with primary biliary cirrhosis (stages II-IV). Pruritus and fatigue improved, and alkaline phosphatase and liver transferases declined significantly in all patients during therapy. In four patients, less inflammation was noted by liver biopsy after 2 yr, but histology of disease did not change. Serum and urinary bile acids were increased several-fold before treatment, with cholic acid predominating. Ursodiol accounted for 30% of biliary bile acids after administration (gallstone subjects ≃ 50%), and was conjugated with glycine and taurine in a ratio of 7.3:1. However, in the endogenous bile acids, the ratio increased from 1.2:1 to only 2.1:1. About 6% unconjugated bile acids were secreted into the bile (healthy controls < 1%). Thus, in patients with primary biliary cirrhosis, a larger fraction of free bile acids and a higher proportion of taurine-conjugated bile acids are secreted into the bile, compared with healthy controls. Ursodiol improves symptoms and histology with lower biliary enrichment with this bile acid.

AB - The effect of ursodiol on the clinical and biochemical features, serum, urinary, and biliary bile acids was investigated over a 2-yr treatment period in 14 patients with primary biliary cirrhosis (stages II-IV). Pruritus and fatigue improved, and alkaline phosphatase and liver transferases declined significantly in all patients during therapy. In four patients, less inflammation was noted by liver biopsy after 2 yr, but histology of disease did not change. Serum and urinary bile acids were increased several-fold before treatment, with cholic acid predominating. Ursodiol accounted for 30% of biliary bile acids after administration (gallstone subjects ≃ 50%), and was conjugated with glycine and taurine in a ratio of 7.3:1. However, in the endogenous bile acids, the ratio increased from 1.2:1 to only 2.1:1. About 6% unconjugated bile acids were secreted into the bile (healthy controls < 1%). Thus, in patients with primary biliary cirrhosis, a larger fraction of free bile acids and a higher proportion of taurine-conjugated bile acids are secreted into the bile, compared with healthy controls. Ursodiol improves symptoms and histology with lower biliary enrichment with this bile acid.

UR - http://www.scopus.com/inward/record.url?scp=0027265104&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027265104&partnerID=8YFLogxK

M3 - Article

C2 - 8480734

AN - SCOPUS:0027265104

VL - 88

SP - 691

EP - 700

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 5

ER -